A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

July 31, 2017

Conditions
AmyloidosisSystemic Light Chain Amyloidosis
Interventions
DRUG

Carfilzomib

IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.

DRUG

Dexamethasone

Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.

Trial Locations (10)

10032

Columbia University, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

19104

Abramson Cancer Center at the University of Pennsylvania, Philadelphia

27710

Duke University Medical Center, Durham

30322

Winship Cancer Institute of Emory University, Atlanta

91010

City of Hope, Duarte

94305

Stanford Cancer Institute, Stanford

97239

Oregon Health and Sciences University, Portland

02118

Boston University Medical Center, Boston

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Criterium, Inc.

INDUSTRY

NCT01789242 - A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis | Biotech Hunter | Biotech Hunter